Hemodiafiltration (HDF) is a renal replacement therapy which is based on the principles of diffusion and convection for the elimination of uremic toxins. A significant and increasing number of end stage renal disease (ESRD) patients are treated with HDF, even in the absence of definite and conclusive survival and anemia treatment data. However, its effects on red blood cell (RBC) physiological features have not been examined in depth. In this study, ESRD patients under regular HDF or conventional hemodialysis (cHD) treatment were examined for RBC-related parameters, including anemia, hemolysis, cell shape, redox status, removal signaling, membrane protein composition and microvesiculation, in repeated paired measurements accomplished before and right after each dialysis session. HDF-group was characterized by better redox potential and suppressed exovesiculation of blood cells compared to the cHD-group pre-dialysis. However, HDF was associated with a temporary but acute, oxidative stress-driven increase in hemolysis, RBC removal signaling and stomatocytosis, probably associated with the effective clearance of dialyzable natural antioxidant components, including uric acid, from the uremic plasma. The nature of these adverse short-term effects of HDF on post-dialysis plasma and RBCs strongly suggests the use of a parallel antioxidant therapy during the HDF session.
. Hemodialysis (HD) is a renal replacement therapy that targets to the elimination of uremic toxins and water excess from blood. Conventional hemodialysis (cHD) , which provides diffusive clearance of low MW solutes, is the main modality of renal replacement therapy for ESRD patients worldwide. The more recently introduced hemodiafiltration (HDF), which uses a combination of convective and diffusive processes for solute removal, seems to have higher biocompatibility and efficiency in the clearance of uremic solutes across a wider MW range, including middle sized β 2 -microglobulin, homocysteine, polyamines and other molecules that influence the endothelial function (Penne et al. 2010 ). In addition, several studies have suggested that HDF may better control hemodynamic stability, inflammation and iron availability, redox status, erythropoiesis and ESA resistance, and even mortality (probably dose-dependent on the achievement of a critical convection volume), when compared with conventional HD (Maduell et al. 2013; Marcelli et al. 2016; Mercadal et al. 2016 ). On the other hand, the superiority of this renal replacement therapy compared to the cHD is still a matter of debate, because data on the effectiveness of HDF on several clinical parameters, ranging from anemia to hard endpoints, are conflicting (Karamperis et al. 2005; Susantitaphong et al. 2013; Vilar et al. 2009 ). In fact, despite the extended (spanning more than two decades) clinical experience with both cHD and HDF, there are no conclusive evidence from large-scale prospective randomized controlled trials to validate the translatability of the current findings on clinical outcomes, including renal anemia (Ronco 2011; Wiecek and Piecha 2015) . In spite of this, there are still no studies reported, describing adverse outcomes to support that HDF is inferior to cHD in any relevant clinical parameters (Basile et al. 2017 (Abed et al. 2014; Georgatzakou et al. 2016) ; 2) The results of large clinical trials pointed out that treatment of severe anemia in ESRD by ESAs seems to be more complex that initially appreciated (Wiecek and Piecha 2015) ; and finally, 3) A significant and increasing number of ESRD patients are treated with HDF, even in the absence of definite and conclusive anemia treatment and survival data. Thus, the present study focused on differences observed in the RBC physiology and performance between HDF-and cHDtreated ESRD patients which are probably related to the management of anemia secondary to ESRD. 
Materials and methods

Subjects
Laboratory testing and immunoblotting of RBC membrane proteins
Hematological analysis, standard biochemical tests in the serum and electrolyte estimation were performed by using automatic blood cell counter and analyzers, respectively. Plasma free hemoglobin (fHb) levels, as an index of intravascular hemolysis, were calculated by the method of Harboe (Harboe 1959) . After a double centrifugation of plasma at 1,000 g for 10min, supernatants were incubated for 30 min at 20 °C and absorbance was measured at 380, 415 and 450nm. The formula: 2xOD415 -OD380 -OD450 was used for the calculation of final OD.
Purified leukodepleted RBC fractions were prepared by the method of Beutler (Beutler et al. 1976 ) and membranes were isolated by RBC lysis with hypotonic (5 mM) sodium phosphate buffer (pH 8.0) containing protease inhibitors. Equal amounts of membrane protein (15 μg) were resolved in 10% SDS-PAGE gels, electrophoretically transferred onto nitrocellulose membranes and immunoblotted against major membrane proteins (Antonelou et al. 2014 ). Subsequently, membrane was incubated with the appropriate horseradish peroxidase-conjugated secondary antibody and the immunoreactivity was visualized by enhanced chemiluminescence. The protein bands were quantified in units of intensity by using lengthwise scanning densitometry and an image-processing program (Gel Analyzer v.1.0, Biosure, Athens, Greece).
Redox status of plasma and RBCs
Total (TAC), uric acid-dependent (UAdAC) and uric acid-independent (UAiAC) antioxidant capacity of plasma were measured by the ferric reducing antioxidant power assay (Benzie and Strain 1996) , with/without uricase treatment (0.125U/mL, for 20 min at 20 o C) (Duplancic et al.
2011
). Briefly, plasma was incubated with freshly prepared working FRAP solution (containing 300mM acetate buffer pH3.6, 10mM 2,4,6-tripyridyl-s-triazine in 40mM HCl and 20 mM FeCl3 in 10:1:1 ratio) and incubated for 4min at 37 °C in a water bath. Absorbance was measured at 593nm.
D r a f t
Intracellular accumulation of reactive oxygen species (ROS) with/without stimulation by 100μM tert-butyl hydrperoxide (tBHP) was detected fluorometrically (VersaFluor Fluorometer) by using the fluorescent probe CMH 2 DCFDA (Invitrogen), as previously described (Antonelou et al. 2014 ).
Scanning electron microscopy and flow cytometry analysis of RBCs and microvesicles
Isolated RBCs were fixed by 2% glutaraldehyde, post-fixed with 1% osmium tetroxide, dehydrated in ascending ethanol series and examined in a Philips SEM515 microscope after coating with gold-palladium (Tousimis Samsputter-2a, Rockville, Maryland). RBC shape classification was performed by using standard criteria, as previously adopted (Antonelou et al. 2011) .
Enumeration, phenotyping, and phosphatidylserine (PS) exposure on RBCs and microvesicles (MVs) were performed by multicolor flow cytometry using the phycoerythrin (PE)-Annexin V apoptosis kit and FITC-conjugated anti-CD235 (BD Pharmingen), as previously described (Tzounakas et al. 2016 ). MVs were identified by size (<1 μm), exposure of RBC-specific markers (anti-CD235) and PS exposure (through annexin V binding, AnnV + ) in plasma isolated after a double 2,500 g spin of citrated blood at 20°C.
Statistical analysis
All which decreased significantly post-dialysis in both groups (Table 1) .
ESRD RBCs were more susceptible to phosphatidylserine (PS) externalization than healthy RBCs, independently of the dialysis technique applied. Yet, the percentage PS + RBCs was significantly lower (P =0.026) in HDF than in cHD patients before dialysis (1.13±0.38% vs 1.73±0.67%, respectively) ( Figure 1A ). Of note, dialysis method had a different impact on PS exposure on RBCs, since HDF increased it significantly (by 40%, P =0.031) compared to the predialysis levels, in opposite to the cHD ( Figure 1A) . Likewise, HDF exhibited a negative effect on D r a f t 9 baseline hemolysis (increase from 15.1±6.6 mg/dL to 17.9±7.4 mg/dL, P =0.026 vs controls, Figure   1B ), intracellular ROS accumulation (from 457±201 to 480±162 RFU, P =0.011 vs controls, Figure   1C ), and on exogenously-induced intracellular ROS levels (from 630±273 to 717±232 RFU, P =0.009 vs controls, Figure 1D ), in striking contrast to a trend for amelioration (fHb, Figure 1B ) or neutral effect (ROS, Figure 1C and 1D) of cHD on those physiological features.
Examination of RBC shape, revealed a trend for stomatocytic transformation in HDF RBCs pre-dialysis that was actively promoted by the dialysis session, resulting in significantly higher percentage of stomatocytes in HDF patients compared to the cHD patients post-dialysis (8.8±2.6% vs 6.2±2.1%, respectively, P =0.023) (Figure 2A and B). Stomatocytosis was positively correlated with serum uric acid levels (r=0.810, P =0.004) but negatively with the percentage of PS + RBCs (r=-0.684, P =0.043) in HDF patients pre-dialysis.
As expected, the uremic plasma was further characterized by pathological accumulation of total (MVs) and RBC-derived (R-MVs) circulating microvesicles ( Figure 2C, cHD: 1,044 ± 627 vs. healthy subjects 130 ± 85 counts/μL) ( Figure 2C , right panel). In many patients treated by cHD, a significant reduction in R-MVs compared to the pre-dialysis levels was recorded, however, that reduction was not a statistically significant feature of cHD-group (P =0.080) owing to high patient-to-patient variation.
Finally, the RBC membrane of HDF-treated patients was characterized by severe deficiency in aquaporin 1 (47±7%, P =0.025) and overexpression of Hsp70 (254±31%, P =0.015) compared to D r a f t healthy subjects (100%), but also, by significantly lower levels of stomatin compared to the membrane of cHD patients pre-dialysis (81±11% vs. 126±10%, respectively, P=0.009). The RBC membrane of cHD-treated subjects on the other side was severely deficient in CD47 (46±11%, P=0.004) but over-expressed Glut 1 (251±38%, P=0.016) and IgGs (693±211%, P=0.033) molecules ( Figure 3A) . Following an HDF session, increased membrane binding of oxidized/denatured Hb was observed (182±68%, P=0.047) ( Figure 3B bar-graph and insert). cHD seemed to be associated with an overall reduction in the expression level of several membrane proteins, including stomatin (77±9%, P=0.005, Figure 3B ). In some cases, that reduction tended to regularity (as in the case of Glut 1) but in other, cHD leaded to protein deficiency (aquaporin 1, 62±8%, P=0.044) or just exacerbated an existing shortage (CD47, from 46±11% to 23±5%, P=0.010).
Discussion
Reduced lifespan and pathologic modifications in circulating RBCs arising from various types of uremic and dialysis-induced stresses, contribute to anemia and other hematological complications in ESRD. While conventional hemodialysis has been studied in respect to its probable effects on RBC morphology and physiology (Antonelou et al. 2014; Antonelou et al. 2011), whether and to what extent hemodiafiltration represents a stress factor for blood cells, or whether it is more "friendly" for them as a renal replacement therapy compared to the cHD, is largely unknown.
The present comparative study assessed an array of functionally important physiological features of circulating RBCs in patients regularly treated by either HDF or cHD.
According to the analysis, greater urea reduction ratio was recorded in patients treated by the end product of purine metabolism in human is a potent natural antioxidant factor, that protects both plasma (in the antioxidant capacity of which it contributes by 35-65%) and cells from oxidative damages, through its free radical scavenging capacity (Assis et al. 2015; Tzounakas et al. 2015) . Of note, either as an indicator of better nutritional status or not, low UA has been proposed as a mortality risk factor in HD patients (Beberashvili et al. 2015) and more recently, it was found that RBC life span (that is a significant measure of/contributor to anemia) in dialysis patients is positively correlated with levels of uric acid and blood urea nitrogen (Ma et al. 2017) . The high clearance D r a f t 13 potential of HDF probably results in the acute elimination of additional dilute factors that also function in strengthening the antioxidant defense reactions in plasma, including albumin (Ahrenholz et al. 2004) , vitamins (Morena et al. 2002) and trace elements (Prodanchuk et al. 2014) .
Trace elements are cofactors for many antioxidant enzymes of blood (Chan et al. 1998) , albumin is a main antioxidant protein of plasma contributing to its free-radical trapping capacity, whereas hydrophobic vitamin C helps vitamin E to work in lipid detoxification.
Thus, while in general, dialysis therapy per se seems to negatively affect the systemic redox status and the RBC antioxidant defenses (Poulianiti et al. 2016) , HDF in particular, seemed to be associated with an additional temporary acute oxidative stress. The effective elimination of "waste" natural antioxidant factors from the uremic plasma by the HDF is manifested in the pathological levels of ROS accumulation and susceptibility to oxidative stimuli that were exclusively observed in HDF-RBCs right after the completion of the dialysis session. Oxidative stress of that origin, was further highlighted by the accumulation of oxidized/denatured Hb to the RBC membrane, the acute increase in PS externalization, the increased intravascular hemolysis (Quaye 2015) and, probably, by the appearance of transient stomatocytosis in HDF-treated patients.
Eryptosis, which is strongly associated with oxidative stress and ceramide formation in uremia, is further triggered by the dialysis procedure (Abed et al. 2014) , while deficiency in reduced GSH has been related to higher risk of hemolysis in ESRD (Weinstein et al. 2000) . The tripeptide GSH is an important antioxidant molecule that can easily pass through filters' pores, especially in HDF, where convection reinforces the removal of substances. The release of free, extracellular Hb and its degradation products in post-dialysis plasma is expected to induce oxidative stress in HDF-blood, as a part of a toxic feedback loop (Quaye 2015) . Post-HDF RBC hemolysis and PS exposure, a marker of oxidative stress for RBCs (Mandal et al. 2002) , might also represent adverse effects of that temporary increase in oxidative stimuli. Appearance of stomatocytes, which represent reversible D r a f t 14 RBC modifications, has been also related with various oxidative and inflammatory states (Gyawali et al. 2015) . Stomatocytes are generally considered as the morphological change adopted by erythrocytes during their response to oxidants (Vota et al. 2013) . Notably, in our patients, the stomatocytic transformation of RBCs was positively correlated with serum uric acid levels and seemed to be a feature of the HDF-group by many ways: HDF-RBCs were characterized by lower membrane expression of stomatin and its membrane protein partners (Rungaldier et al. 2013) aquaporin 1 and glucose transporter 1, compared to the cHD-RBCs, and, moreover, stomatocytosis was triggered by HDF and not by cHD. HDF-associated membrane-perturbing cationic factors might also induce a stomatocytic transformation of RBC morphology through preferential accumulation in, and therefore expansion of, the inner (relative to the outer) leaflet of the lipid bilayer . Stomatocytosis is expected to affect cation permeability and intrinsic deformability of the membrane, as well as RBC aggregation and filterability in the microcirculation of HDF-treated ESRD group post-dialysis (Chabanel et al. 1987; Reinhart and Chien 1986) .
Moreover, uremia and dialysis-associated stresses trigger exovesiculation in blood cells (Boulanger et al. 2007 ). Our patients (especially those of the cHD group) were characterized by over-accumulation of MVs to plasma, compared to healthy subjects. Dialysis lowered the mixed population of plasma MVs (where MVs of platelet, RBC, leukocyte, and endothelial origin are found) to normal levels, but it had minor effects on RBC-derived MVs, especially in the HDF group, suggesting dialysis-triggered neo-vesiculation of RBC membrane. To support this assumption, a trend for lower post-dialysis R-MVs levels was observed in cHD-treated patients compared to the pre-dialysis levels (despite at no statistically significant point due to high inter-patient variability), in whom post-dialysis oxidative stress (an established trigger of vesiculation in RBCs) remained at normal levels, in opposite to the HDF-treated patients. Moreover, the increased stomatocytic D r a f t 15 transformation seen in HDF-RBCs post-dialysis is expected to inhibit exovesiculation of the membrane (Schreier et al. 2000) .
Although the time-course evaluation of this effect needs further studies of HDF-treated patients post-dialysis, our results suggest that application of HDF should be combined with antioxidant protection of blood during the dialysis or soon after it, to mitigate the increases in intravascular hemolysis, RBC removal signaling and exovesiculation. Oral or intravenous supplementation of reduced glutathione, L-carnitine and vitamin C has been shown to improve lifespan, metabolism and other physiological properties of RBCs (Candan and Gultekin 2002; Usberti et al. 1997 ). In addition, intravenous infusion of reduced GSH or vitamin C soon after dialysis by vitamin-E coated membranes was shown to improve anemia and ameliorate erythropoietin requirements in hemodialysis patients (D'Arrigo et al. 2017; Usberti et al. 2002; Yang et al. 2006 ).
To our knowledge, this study is the first to evaluate the effects of HDF on overall RBC biology and performance in ESRD patients. However, there are several limitations. First, the patient population was relatively small and thus some measurements that obviously differed between groups but exhibited high inter-patient variation were not found statistically significant. To overcome that limitation, we tried to construct as much as possible homogeneous patient groups (in terms of demographic and clinical data) and moreover, we performed repeated paired measurements (at least three per patient) before and soon after the dialysis session to increase the statistical power of the study. Second, direct inflammation markers such as high sensitivity Creactive protein and interleukins were not measured and thus our results cannot be directly D r a f t D r a f t 
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